ALKEM
Inspiring Healthier Lives

ALKEM LABORATORIES LTD.
Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.
• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

17th August, 2026

To,

The Corporate Relationship Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. ***Scrip Code: 539523***	**National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. ***Scrip Symbol: ALKEM***

Ref: In the matter of scheme of amalgamation between Alkem Laboratories Limited ("Company") and Adroit Biomed Limited ("ABL") under Sections 230 to 232 read with other relevant provisions of the Companies Act, 2013 ("Scheme" or "Scheme of Amalgamation").

Sub: Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer's Report on e-voting (remote e-voting and e-voting at the Meeting)

Dear Sir/Madam,

We enclose herewith the following in connection with the meeting of the equity shareholders of the Company convened pursuant to the Order dated June 10, 2026, passed by the Hon'ble National Company Law Tribunal, Mumbai Bench and held on Monday, August 17, 2026:

1. Summary of the proceedings of the Meeting
2. Scrutinizer's Report on e-voting (remote e-voting and e-voting at the Meeting).

Sincerely,

For Alkem Laboratories Limited

MANISH NARANG Digitally signed by MANISH NARANG Date: 2026.08.17 18:50:53 +05'30'

Manish Narang
President – Legal, Company Secretary & Compliance Officer
Encl: a/a

ALKEM LABORATORIES LTD.
Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.
• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

Summary of proceedings of the meeting of the equity shareholders of the Company convened pursuant to the Order of Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT Mumbai") and held on Monday, August 17, 2026 ("Meeting")

A. Date, time and venue of the Meeting

The Meeting of the equity shareholders of the Company convened pursuant to the Order dated June 10, 2026, passed by NCLT Mumbai was held on Monday, August 17, 2026 at 11:00 a.m. (IST) through video conferencing/other audio visual means ("**VC/OAVM**").

B. Proceedings in brief

Mr. Harihar Prakash Chaturvedi, former Additional Secretary, Government of India, Ministry of Law and Justice and Judicial Member of the NCLT Mumbai, chaired the Meeting ("**Chairperson**").

The Chairperson called the Meeting to order and commenced at 11:15 a.m., the requisite quorum being present.

The Chairperson thereafter stated that the Meeting was held through VC/OAVM in compliance with the directions of the Order of NCLT Mumbai dated June 10, 2026. The Chairperson thereafter addressed the equity shareholders. The equity shareholders were then informed that the remote e-voting commenced at 9:00 a.m. (IST) on Wednesday, August 12, 2026 and concluded at 5:00 p.m. (IST) on Sunday, August 16, 2026.

Scheme of Amalgamation between Adroit Biomed Limited ("**Transferor Company**") and Alkem Laboratories Limited ("**Transferee Company**"/ "**Company**") ("**Scheme**") was placed before the equity shareholders for consideration and approval.

The Chairperson informed the equity shareholders that Mr. Ritul Parmar, a practicing Company Secretary, was appointed as the Scrutinizer to scrutinize the voting through electronic means (i.e., remote e-voting and voting at the Meeting by using electronic system) ("**e-voting**").

The Chairperson informed the equity shareholders that the results of e-voting shall be disseminated to the stock exchanges and also uploaded on the website of the Company and Central Depository Services (India) Limited, providing remote e-voting prior to the Meeting and e-voting during the Meeting through VC/OAVM.

C. Voting by equity shareholders

The Company had provided remote e-voting facility to its equity shareholders to cast votes electronically on the business set out in the Notice of the Meeting from 9:00 a.m. (IST) on Wednesday, August 12, 2026 to 5:00 p.m. (IST) on Sunday, August 16, 2026.

Further, the facility to vote on the resolution through electronic voting system at the Meeting was made available to the equity shareholders who participated in the Meeting and had not cast their votes through remote e-voting.

D. Results of e-voting (remote e-voting and e-voting at the Meeting)

Votes in favour – 99.9999%

Note: This document does not constitute the minutes of the proceedings of the Meeting of the Company.

For **Alkem Laboratories Limited**

MANISH NARANG Digitally signed by MANISH NARANG Date: 2026.08.17 18:51:16 +05'30'

Manish Narang
President – Legal, Company Secretary & Compliance Officer
Place: Mumbai
Date: August 17, 2026

Hon’ble National Company Law Tribunal convened meeting of the equity shareholders of Alkem Laboratories Limited

Date of Meeting : 17th August, 2026

Total number of shareholders on record date : 63667

No. of shareholders present in the meeting either in person or through proxy: Not Applicable

Promoters and Promoter Group: 0

Public: 0

No. of shareholders attended the meeting through video conferencing (“VC”) / Other Audio Visual Means ("OAVM"):

Promoters and Promoter Group: 5

Public: 32

Alkem Laboratories Limited

Resolution Required :Special	**1 - Approval of the Scheme of amalgamation between Adroit Biomed Limited and Alkem Laboratories Limited under Sections 230-232 and other applicable provisions of the Companies Act, 2013.**
Whether promoter/ promoter group are interested in the agenda/resolution?	**No**

Category	Mode of Voting	No. of shares held	No. of votes polled	% of Votes Polled on outstanding shares	No. of Votes – in favour	No. of Votes –Against	% of Votes in favour on votes polled	% of Votes against on votes polled
		[1]	[2]	[3]={[2]/[1]}*100	[4]	[5]	[6]={[4]/[2]}*100	[7]={[5]/[2]}*100
Promoter and Promoter Group	E-Voting	59424889	56492801	95.0659	56492801	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot		0	0.0000	0	0	0.0000	0.0000
	Total		**56492801**	**95.0659**	**56492801**	**0**	**100.0000**	**0.0000**
Public Institutions	E-Voting	39607384	37130858	93.7473	37130858	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot		0	0.0000	0	0	0.0000	0.0000
	Total		**37130858**	**93.7473**	**37130858**	**0**	**100.0000**	**0.0000**
Public Non Institutions	E-Voting	20532727	6361637	30.9829	6361553	84	99.9987	0.0013
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot		0	0.0000	0	0	0.0000	0.0000
	Total		**6361637**	**30.9829**	**6361553**	**84**	**99.9987**	**0.0013**
Total		**119565000**	**99985296**	**83.6242**	**99985212**	**84**	**99.9999**	**0.0001**

Form MGT-13

CONSOLIDATED SCRUTINIZER'S REPORT ON REMOTE E-VOTING AND E-VOTING

[Pursuant to Section 108 of the Companies Act, 2013 and Companies (Management and Administration) Rules, 2014]

August 17, 2026

To,

The Chairperson appointed by the National Company Law Tribunal, Mumbai Bench for the meeting of the Equity Shareholders of ALKEM LABORATORIES LIMITED

Registered Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai, Maharashtra, India, 400013

CIN: L00305MH1973PLC174201

Sub: Consolidated Scrutinizer's Report on the results of voting by the Equity Shareholders of Alkem Laboratories Limited through remote e-voting process (prior to the Meeting) and at the Meeting held on 17th August 2026 at 11:00 a.m. (IST) through video conferencing / other audio visual means, convened pursuant to the directions of the Hon'ble National Company Law Tribunal, Mumbai Bench vide its Order dated June 10, 2026 in Company Scheme Application No. 44/MB/2026 in the matter of the Scheme of Amalgamation between Adroit Biomed Limited and Alkem Laboratories Limited.

Dear Sir,

I, Ritul Parmar, Practicing Company Secretary, have been appointed by the Hon'ble National Company Law Tribunal, Mumbai Bench, by its Order dated June 10, 2026 passed in Company Scheme Application No. 44/MB/2026 ("Order"), as the Scrutinizer for the purpose of scrutinizing the remote e-voting process prior to the Meeting and e-voting process at the Meeting of the equity shareholders of Alkem Laboratories Limited, convened and held on Monday, August 17, 2026 at 11:00 a.m. (IST) through video conferencing ("VC") / other audio visual means ("OAVM"), in compliance with the applicable provisions of the Companies Act, 2013 ("Act"), the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), and the directions of the Hon'ble Tribunal, in a fair and transparent manner, on the resolution seeking approval of the equity shareholders to the proposed Scheme.

After ascertaining the requisite quorum, the Meeting commenced at 11.15 a.m. (IST).

I do hereby submit my report as under:

1. As confirmed by the Company, the Notice dated 15th July 2026 along with the Scheme of Amalgamation, statement under Sections 230 to 232 read with Section 102 and other applicable provisions of the Act and Rule 6 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 ("Merger Rules") along with the annexures thereto ("Notice") was sent to the equity shareholders of the Company in respect of the resolution proposed at the Meeting.

2. Pursuant to the directions of the Hon'ble Tribunal vide the Order, the Company had also published the notice of the Meeting in Business Standard(English) and Navshakti(Marathi) on July 16, 2026.

3. The Company had provided to its equity shareholders the facility to exercise their right to vote on the resolution proposed to be considered at the Meeting through electronic means by using the electronic voting system provided by Central Depository Services (India) Limited ("CDSL") (remote e-voting).

4. The Company had also provided e-voting facility to the equity shareholders present at the Meeting through VC/OAVM who had not cast their votes through remote e-voting prior to the Meeting.

5. The voting period for the remote e-voting prior to the Meeting commenced on Wednesday, August 12, 2026 at 9:00 a.m. (IST) and ended on Sunday, August 16, 2026 at 5:00 p.m. (IST).

6. The cut-off date was Monday, August 10, 2026 for the purpose of determining the equity shareholders entitled to vote through remote e-voting and e-voting conducted at the Meeting on the resolution seeking their approval.

Rp

7. After the closure of the e-voting at the Meeting, the report on the e-voting done at the Meeting and the votes cast under remote e-voting facility prior to the Meeting were unblocked at 1.07 pm and counted.

8. I have scrutinized and reviewed the remote e-voting and votes tendered therein based on the data downloaded from the CDSL e-voting system. The downloaded data was reconciled with the records of the Company / Register of Members / List of Beneficiaries and the authorisations lodged with the Company, as applicable.

9. The Chairperson is responsible to ensure compliance with the requirements of the Act and Rules thereunder and the SEBI Listing Regulations relating to voting through remote e-voting and e-voting at the Meeting on the resolution contained in the Notice.

10. My responsibility as the Scrutinizer for the remote e-voting process and e-voting at the Meeting is restricted to scrutinize the remote e-voting process prior to the Meeting and e-voting process at the Meeting in a fair and transparent manner and to prepare a consolidated Scrutinizer's Report of the votes cast "in favour" or "against" the Resolution and "invalid" votes, based on the reports generated from the remote e-voting system and e-voting at the Meeting provided by CDSL.

11. The resolution placed before the equity shareholders and the consolidated result of the voting on the same through remote e-voting prior to the Meeting and e-voting process during the Meeting seeking approval of the equity shareholders of the Company, are given below:-

"RESOLVED THAT pursuant to the provisions of Sections 230 to 232 of the Companies Act, 2013 ("Act"), and any other applicable provisions of the Act, (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the rules, circulars and notifications made thereunder as may be applicable, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), and the applicable circulars thereunder issued by the Securities and Exchange Board of India ("SEBI") and as amended from time to time and relevant provisions of other applicable laws, the provisions of the Memorandum of Association and Articles of Association of the Company, and subject to the approval of the Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") and / or the National Company Law Appellate Tribunal or such other forum or authority as may be vested with the appellate jurisdiction in this regard and subject to such other approvals, permissions and sanctions of regulatory and other authorities, as may be necessary and subject to such conditions and modifications as may be deemed appropriate, at any time and for any reason whatsoever, or which may otherwise be considered necessary, desirable or as may be prescribed or imposed by the NCLT or by any regulatory or other authorities, while granting such approvals, permissions and sanctions, which may be agreed to by the Board of Directors of the Company (hereinafter referred to as the "Board" which term shall be deemed to mean and include one or more Committee(s) constituted/to be constituted by the Board or any person(s) which the Board may nominate to exercise its powers including the powers conferred by this resolution), the proposed scheme of amalgamation between Adroit Biomed Limited and Alkem Laboratories Limited under Sections 230-232 and other applicable provisions of the Act and other applicable regulatory requirements (the "Scheme"), as per the draft enclosed to the Notice, be and is hereby approved.

RESOLVED FURTHER THAT for the purpose of giving effect to the above resolution and for removal of any difficulties or doubts, the Board, be and is hereby authorized to do all such acts, deeds, matters and things, as it may, in its absolute discretion, deem desirable, necessary, expedient, usual or proper, and to settle any questions or difficulties or doubts that may arise, including passing of such accounting entries and/or making such adjustments in the books of accounts, transfer/vesting of such assets and liabilities as considered necessary to give effect to the above resolution, settling of any questions or difficulties arising under the Scheme or in regard to and of the meaning or interpretation of the Scheme or implementation thereof or in any matter whatsoever connected therewith, or to review the position relating to the satisfaction of various conditions of the Scheme and if necessary, to waive any of those, and to make modifications, amendments, revisions, edits and all other actions as may be required to finalise the Scheme and do all acts, deeds and things as may be necessary, desirable or expedient for carrying the Scheme into effect or to carry out such modifications/directions as may be required and/or imposed and/or permitted by the NCLT while sanctioning the Scheme, or by any governmental authorities, to do and perform and to authorize the performance of all such acts and deeds which are necessary or advisable for the implementation of the Scheme and upon the sanction of the Scheme by, amongst others, the NCLT and/or SEBI and/or any other regulatory/Government authorities, to implement and to make the Scheme effective, without any further approval of the shareholders or to approve withdrawal (and where applicable, re-filing) of the Scheme at any stage for any reason including in case any changes and/or modifications are suggested/required to be made in the Scheme or any condition suggested, required or imposed, whether the

RP

SEBI, the NCLT, and/or any other authority, are in the Board's view not acceptable to the Company, and/or if the Scheme cannot be implemented otherwise, and to do all such acts, deeds and things as it may deem necessary and desirable in connection therewith and incidental thereto, to approve and authorize execution of any agreements, deeds, documents, declarations, affidavits, writings, etc. (including any alterations or modifications in the documents executed or to be executed), whether or not under the Common Seal of the Company, as may be required from time to time in connection with the Scheme.

RESOLVED FURTHER THAT a copy of this resolution certified by any one of the Directors and/or the Company Secretary of the Company be submitted to the concerned authorities and they be hereby requested to act upon the same."

12. The details of the Consolidated Results of the voting by equity shareholders of the Company [by remote e-voting prior to the Meeting and e-voting at the Meeting] are as under:

Mode of Voting	No. of Equity Shareholders Polled	Votes Polled	Equity Shareholders Voted in Favour	% of total no. of Equity Shareholders Voted in Favour	Votes in Favour	% of Votes in Favour	Equity Shareholders Voted Against	% of total no. of Equity Shareholders Voted Against	Votes Against	Invalid Votes
Remote E-Voting	872	9,99,84,489	861	99.9999%	9,99,84,405	99.9999%	11	0.0001%	84	0
E-Voting at Meeting	7	807	7	100.0000%	807	100.0000%	0	0.0000%	0	0
Total	**879**	**9,99,85,296**	**868**	**99.9999%**	**9,99,85,212**	**99.9999%**	**11**	**0.0001%**	**84**	**0**

13. The Scheme shall be considered approved by the equity shareholders only if approved by majority of persons representing three-fourth in value of the equity shareholders of the Company, voting through remote e-voting and e-voting facility made available during the Meeting through VC/OAVM.

1. Voted in favour of the resolution:

Particulars	Remote e-voting	E-voting at the Meeting	Total Voting
Number of equity shareholders voted	861	7	868
Number of valid votes cast by them	9,99,84,405	807	9,99,85,212

% of total numbers of valid votes cast (in favour): 99.9999%

2. Voted against the resolution:

Particulars	Remote e-voting	E-voting at the Meeting	Total Voting
Number of equity shareholders voted	11	0	11
Number of valid votes cast by them	84	0	84

% of total numbers of valid votes cast (against): 0.0001%

3. Invalid votes:

Particulars	Remote e-voting	E-voting at the Meeting	Total Voting
Number of equity shareholders voted	0	0	0
Number of invalid votes cast by them	0	0	0

% of total numbers of invalid votes cast: 0%

RP

14. Based on the aforesaid results, we report that the resolution as contained in the Notice of the Meeting has been **PASSED** with the requisite majority.

15. All registers, relevant records and other incidental papers related to remote e-voting prior to the Meeting and e-voting at the Meeting were handed over to the Company Secretary of the Company for safe keeping.

Thanking you,
Yours truly,

For Ritul Parmar, Company Secretaries

Rparmar

Ritul Parmar
Membership No: F13125 CP No: 14845
Dated: August 17, 2026
Peer Review No. 2586/2022
Place: Navi Mumbai
UDIN: F013125H001130661

Ritul Parmar, Company Secretaries
FCS No.13125
CP No. 14845

Countersigned by

Harihar Prakash Chaturvedi
Chairperson appointed by the Hon'ble NCLT for the Meeting